Drug Trial Radar · NCT00792740
Effect of ITF2357 on Mucosal Healing in Patients With Moderate-to-severe Active Crohn's Disease
Last checked: Nov 19, 2026Latest source record: Jul 19, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
51
Actual
Start
Oct 22, 2007
Primary completion
Dec 2008
Study completion Mar 11, 2009
Sponsor
- Lead sponsor
- ItalfarmacoIndustry
- Sponsor type
- Industry
- First posted
- Nov 18, 2008
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Objectives: The primary objective of the study was to determine the ability of ITF2357, administered orally at the dose of 50 mg b.i.d. for 8 consecutive weeks, to induce complete healing of mucosal ulcerations of ileum and/or colon, assessed by endoscopy, in patients with endoscopic and clinical evidence of active moderate-to-severe Crohn's disease not controlled by conventional therapies. The secondary objectives of the study were: * to evaluate the effect of ITF2357 on endoscopic disease activity assessed using both the Crohn's Disease Endoscopic Index of Severity (CDEIS) and the Simple Endoscopic Score of Crohn's Disease (SES-CD); * to evaluate the effect of ITF2357 on clinical disease activity, assessed using the Crohn's Disease Activity Index (CDAI); * to assess the safety and tolerability of ITF2357; to assess the pharmacokinetic profile of ITF2357.
Conditions
- Crohn's Disease
Interventions
ITF2357Drug
ITF2357 was administered as hard gelatin capsules for oral administration at the dose strength of 50 mg. Capsules were administered as follow: one capsule in the morning and one in the evening.
PlaceboOther
Placebo was supplied as matching capsules for oral administration with the same outer appearance of the study drug and with the same dosing scheme (one capsule in the morning and one in the evening)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Patients Achieving Complete Healing of Mucosal Ulcerations of Ileum and/or ColonTime frame: At week 8
Locations
10 sites in 3 countries. Site status is shown where the registry gives one.
AZ Sint Lucas Gastro-enterologie
Assebroek, Belgium
Imelda Hospital Gastro-enterology dept.
Bonheiden, Belgium
CHU Saint-Pierre Médecine Interne
Brussels, Belgium
UZ Gent Gastro-enterologie 1K12IE
Ghent, Belgium
AZ Groeninge (St-Niklaas) Gastro-enterologie
Kortrijk, Belgium
University Hospital Gasthuisber
Leuven, Belgium
Divisione di Gatroenterologia Istituto Clinico Humanitas IRCCS in. Gastroenterology
Rozzano, Italy
Vrije Universiteit (VU) Medisch Centrum Afdeling M.D.L.ziekten
Amsterdam, Netherlands
Academisch Medisch Centrum (AMC) Afdeling M.D.L. ziekten
Amsterdam, Netherlands
Leids Universitair Medisch Centrum (LUMC) Afdeling M.D.L. ziekten
Leiden, Netherlands
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.